Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (Nasdaq: CODX) reported Q1 2026 revenue of $0.15 million, up from $0.05 million in Q1 2025. Operating expenses were $9.2 million and net loss was $9.1 million, or $4.06 per share. Cash was $8.2 million on March 31, 2026.
Key updates include an Indian CDSCO license and ISO 13485 certification for the CoSara PCR Pro® instrument, South Asia territory expansion lifting TAM to about $13 billion, completion of upper respiratory clinical enrollment, TB study preparations in India, and advancement of a CoMira manufacturing facility in Saudi Arabia.
Co-Diagnostics (Nasdaq: CODX) joint venture CoMira has finalized a lease for a ~14,400 sq ft turnkey manufacturing facility in Sudair Industrial City, Saudi Arabia, advancing localized production of PCR instruments, laboratory equipment and medical consumables.
The lease follows an approved industrial land allocation and aims to support capital-efficient operational readiness, regional distribution across KSA and MENA, and alignment with Saudi Vision 2030, subject to required regulatory clearances.
Co-Diagnostics (Nasdaq: CODX) will release its first quarter 2026 financial results on Thursday, May 14, 2026 after market close. A live conference call and webcast will follow at 4:30 p.m. ET with CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson.
The webcast will be available at ir.co-dx.com on the Events & Webcasts page; a recorded replay will be posted later.
Co-Diagnostics (NASDAQ: CODX) was invited to present its Co-Dx MTB test on the Co-Dx PCR platform at the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026.
The company will present at a roundtable with U.S. government agencies and private-sector stakeholders. According to the company, the platform aligns with recent WHO guidance on near-point-of-care molecular diagnostics and tongue-swab testing. The Co-Dx PCR platform remains under FDA and other regulatory review and is not yet available for sale.
Co-Diagnostics (NASDAQ:CODX) will present at ESCMID Global 2026, April 17-21 in Munich, Germany, showcasing its CE-IVD testing solutions and the upcoming Co-Dx PCR platform.
Company representatives will meet global customers and distributors at Booth #G55. The Co-Dx PCR platform is under regulatory review and not yet for sale.
Co-Diagnostics (Nasdaq-CM: CODX) said executives will join the World Trade Center Utah trade mission with Utah Governor Cox from April 13–22, 2026 for meetings across Switzerland and Germany.
The itinerary includes site visits to Roche Diagnostics, UBS, Zurich Innovation Park, and attendance at ESCMID Global 2026 in Munich. According to the company, the trip supports international partnerships as Co-Dx prepares a 510(k) submission for a real-time PCR point-of-care platform; the platform is under regulatory review and not yet available for sale.
Co-Diagnostics (NASDAQ: CODX) said its joint venture CoMira Diagnostics secured an industrial land allocation in Sudair Industrial City, Saudi Arabia, approved by MODON on April 2, 2026. The site is intended for a molecular diagnostics manufacturing facility; final lease hinges on site infrastructure completion.
The facility aims to localize production of molecular instruments and assays, support Saudi Vision 2030 objectives, and position CoMira among early domestic diagnostic manufacturers; the Co-Dx PCR platform remains subject to regulatory review.
Co-Diagnostics (NASDAQ: CODX) reported full year 2025 results and operational milestones on March 31, 2026. Revenue fell to $0.6M from $3.9M in 2024; operating expenses were $50.6M including an $18.9M intangible impairment. Net loss was $46.9M, or $35.25 per share; cash and securities totaled $11.9M.
Operationally, Co-Dx closed equity offerings raising $10.8M, secured a CDSCO license in India, began instrument and TB test shipments to India, advanced CoSara and CoMira joint ventures, and expanded IP with new patents.
Co-Diagnostics (Nasdaq: CODX) has shipped PCR Pro instruments, Co-Dx PCR MTB test kits and sample-prep devices to joint venture CoSara in India to enable clinical performance studies for a TB test aligned with new WHO 2026 guidance on near-point-of-care molecular testing and tongue swabs. The company also received a CDSCO license to manufacture and sell the PCR Pro instrument in India and says clinical study commencement is expected in the near term while U.S. regulatory review remains ongoing.
Co-Diagnostics (Nasdaq: CODX) expanded its CoSara joint venture commercial territory to include Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the South Asia addressable market to an estimated $13.0 billion. The move supports planned commercialization of the PCR Pro® point-of-care instrument and SARAGENE® tests, subject to regulatory approvals.
CoSara will evaluate regulatory pathways, build distribution channels, and host a virtual distributor session in Q2 2026 with an in-person training meeting planned later in summer 2026.